湖南汉森制药股份有限公司 2023年度内部控制评价报告 湖南汉森制药股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部 控制监管要求（以下简称"企业内部控制规范体系"），结合本公司（以 下简称"公司"）内部控制制度和评价办法，在内部控制日常监督和 专项监督的基础上，我们对公司2023年12月31日（内部控制评价报告 基准日）的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控 制，评价其有效性，并如实披露内部控制评价报告是公司董事会的责 任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、 高级管理人员保证本报告内容不存在任何虚假记载、误导性陈述或重 大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、 财务报告及相关信息真实完整，提高经营效率和效果，促进实现发展 战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部控制变得不恰当，或 - ...

湖南汉森制药股份有限公司 2023 年度独立董事述职报告 湖南汉森制药股份有限公司 2023 年度独立董事述职报告（詹萍） 本人作为湖南汉森制药股份有限公司（以下简称"公司"）的独立董事，严 格按照《公司法》《证券法》《公司章程》等规定和要求，在 2023 年度工作中 诚实、勤勉、独立地履行职责，积极出席相关会议，认真审议董事会各项议案， 对公司重大事项发表了独立意见，切实维护了公司和股东特别是中小股东的利 益，较好地发挥了独立董事作用。现将本人在 2023 年度履行独立董事职责情况 报告如下： 一、基本情况 本人詹萍，出生于 1965 年 8 月，曾任湖南求剑律师事务所副主任，益阳市 第三届、四届、五届、六届人大代表、内务司法委员会委员，益阳市第四届、五 届人大常务委员会委员，第二、三届益阳市律师协会副会长、第四届益阳市律师 协会会长，第五届益阳市律师协会监事长，第六届湖南省律协女律师专门委员会 副主任，第七届湖南省律协法律顾问委员会副主任，第九届中华全国律师协会理 事，湖南汉森制药股份有限公司监事。现任第六届益阳市律师协会荣誉会长，湖 南汉森制药股份有限公司独立董事，湖南义剑律师事务所律师。 报告期内，本 ...

（2024 年 4 月） 内部审计制度 第一章 总 则 湖南汉森制药股份有限公司 第四条 公司在董事会下设审计委员会，财务审计部是审计委员会的职能部门， 独立行使内部审计监督权，对董事会负责并报告工作。 第五条 审计人员应当具备必要的专业知识和实践经验，其专业技术职务资格至 少是会计师或按国家有关规定执行。内部审计人员在企业内部的技术职务资格的确认 和公开聘任，根据公司有关规定执行。 第六条 内部审计人员应当依法审计，忠于职守、坚持原则、客观公正、廉洁奉 公、保守秘密；不得滥用职权、徇私舞弊、泄露秘密、玩忽职守。 第七条 内部审计人员依据相关法律法规和公司有关规定行使内部审计职权，被 审计对象应当积极配合协作，及时向内部审计人员提供相关资料，不得拒绝、阻挠、 破坏及打击报复。 第八条 公司实行内部审计回避制度。凡内部审计人员与审计事项有经济利益关 系及其他利害关系时，该内部审计人员应当回避，并报直接领导部门。如事后才发现 应当回避情形时，由直接领导对该内部审计人员的审计工作进行审查，以决定是否作 为审计证据使用。 第九条 在特定情形下，经公司董事会领导的批准，可以聘请外部专业技术人员 协助解决内部审计工作中遇 ...

Financial Performance - The company's revenue for Q1 2024 was ¥254,032,546.62, representing a 1.54% increase compared to ¥250,177,963.58 in the same period last year[4] - Net profit attributable to shareholders was ¥58,264,674.17, up 5.81% from ¥55,067,482.18 year-on-year[4] - Total operating revenue for Q1 2024 was CNY 254,032,546.62, a 1.5% increase from CNY 250,177,963.58 in Q1 2023[20] - Net profit for Q1 2024 was CNY 58,264,674.17, representing a 4.0% increase compared to CNY 55,067,482.18 in Q1 2023[21] - Basic and diluted earnings per share increased to CNY 0.1158 from CNY 0.1094 year-over-year[22] Cash Flow - The net cash flow from operating activities decreased significantly by 70.89%, amounting to ¥20,503,807.95 compared to ¥70,447,112.49 in the previous year[4] - Cash flow from operating activities generated a net amount of CNY 20,503,807.95, a significant decrease from CNY 70,447,112.49 in the previous year[22] - The net cash flow from investment activities was 1,329,594.94, a significant improvement compared to the negative cash flow of 73,944,830.71 in the previous year[23] - The net cash flow from financing activities was 1,831,534.64, down from 2,045,917.55 in the same period last year[23] - The net increase in cash and cash equivalents for the quarter was 23,664,937.53, a recovery from the negative change of -1,451,800.67 in the same quarter last year[23] Assets and Liabilities - Total assets at the end of the reporting period increased by 2.30% to ¥2,390,145,792.92 from ¥2,336,488,623.93 at the end of the previous year[4] - Total liabilities amounted to CNY 362,718,320.00, a decrease from CNY 373,459,685.26 in the previous year[18] - The company's total current liabilities decreased to ¥342,596,533.69 from ¥355,424,606.90, a reduction of about 3.6%[17] - The total non-current assets stood at ¥1,441,761,018.84, slightly up from ¥1,440,414,236.14, showing a marginal increase[17] Shareholder Information - The company's total equity attributable to shareholders increased by 3.28% to ¥2,027,427,472.92 from ¥1,963,028,938.67 at the end of the previous year[4] - Total equity attributable to shareholders increased to CNY 2,027,427,472.92 from CNY 1,963,028,938.67 year-over-year[18] - The total number of common shareholders at the end of the reporting period is 28,376[14] - Hainan Hansen Holdings holds 42.13% of the shares, making it the controlling shareholder of the company[14] Research and Development - Research and development expenses decreased by 35.92% to ¥7,867,000.00, primarily due to reduced investment in ongoing projects[9] - The company is actively involved in research and development of new products and technologies, although specific details were not disclosed in the report[15] Other Income and Expenses - Other income rose by 77.64% to ¥2,740,000.00, mainly due to government subsidies received during the reporting period[9] - Total operating costs decreased to CNY 193,715,774.24, down 4.8% from CNY 202,676,986.60 in the previous year[20] - Investment income dropped by 64.87% to ¥4,598,000.00, mainly due to decreased returns from equity method investments[9] - Investment income decreased to CNY 4,586,980.33 from CNY 13,056,492.38 in the previous year[21] Future Outlook - Future outlook includes potential market expansion and strategic acquisitions, with a focus on enhancing product offerings and market presence[15] Audit Information - The company has not undergone an audit for the first quarter report[24]

湖南汉森制药股份有限公司 以下情形不适用本节风险投资规范的范围： （一）作为公司主营业务的证券投资与衍生品交易行为； （二）固定收益类或者承诺保本的投资行为； （三）参与其他上市公司的配股或者行使优先认购权利； （四）购买其他上市公司股份超过总股本的 10%，且拟持有三年以上的证 券投资； （五）公司首次公开发行股票并上市前已进行的投资。 风险投资管理制度 （2024 年 4 月） 第一章 总则 第一条 为规范湖南汉森制药股份有限公司（下称"公司"、"本公司"） 的风险投资行为，防范投资风险，强化风险控制，保护投资者的权益和公司利益， 根据《中华人民共和国证券法》《深圳证券交易所股票上市规则》《深圳证券交易 所上市公司自律监管指引第 1 号——主板上市公司规范运作等法律、法规、规范 性文件以及本《公司章程》的有关规定，结合本公司的实际情况，特制定本制度。 第二条 本制度所称的风险投资，包括股票及其衍生品投资、基金投资、期 货投资、以非房地产为主营业务的上市公司从事房地产投资、以上述投资为标的 的证券投资产品、委托理财等其他投资行为。其中，委托理财是指公司委托银行、 信托、证券、基金、期货、保险资产管理机构、金 ...

湖南汉森制药股份有限公司 审 计 报 告 众环审字(2024) 1100069号 审 计 报 告 众环审字（2024）1100069 号 湖南汉森制药股份有限公司全体股东： 一、审计意见 我们审计了湖南汉森制药股份有限公司（以下简称"汉森制药公司"）财务报表，包括 2023 年 12 月 31 日的合并及公司资产负债表，2023 年度的合并及公司利润表、合并及公司 现金流量表、合并及公司股东权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了 汉森制药公司 2023 年 12 月 31 日合并及公司的财务状况以及 2023 年度合并及公司的经营 成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对 财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职 业道德守则，我们独立于汉森制药公司，并履行了职业道德方面的其他责任。我们相信，我 们获取的审计证据是充分、适当的，为发表审计意见提供了基础。 三、关键审计事项 关键审计事项是我们根据职业判断，认为对本期财务报表审 ...

证券代码：002412 证券简称：汉森制药 公告编号：2024-004 湖南汉森制药股份有限公司 湖南汉森制药股份有限公司（以下简称"公司"）第六届监事会第四次会议 于 2024 年 4 月 25 日在公司二楼会议室召开，本次会议由公司监事会主席刘赛 程女士召集主持，会议通知于 2024 年 4 月 15 日以专人递送、传真及电子邮件 等方式送达给全体监事。应参加会议监事 3 人，实际参加会议监事 3 人。本次会 议采取现场会议的方式召开。本次会议的召集、召开符合《中华人民共和国公司 法》及《公司章程》的规定。 二、监事会会议审议情况 （一）审议通过了《2023 年度监事会工作报告》 《2023 年度监事会工作报告》具体内容详见同日公司指定信息披露网站巨 潮资讯（www.cninfo.com.cn）。 本项议案尚需提交公司股东大会审议。 表决结果：3 票赞成；0 票弃权；0 票反对。 （二）审议通过了《2023 年度财务决算报告》 经审核，监事会认为：《2023 年度财务决算报告》系基于中审众环会计师 事务所（特殊普通合伙）出具的标准无保留意见的审计报告所编制，客观、真实 地反映了公司 2023 年度的财务状 ...

湖南汉森制药股份有限公司 机构调研接待工作管理办法 （2024 年 4 月） （三）保密原则 第一章 总则 第一条 为贯彻证券市场公开、公平、公正原则，规范湖南汉森制药股份有 限公司（以下简称"公司"）对外接待行为，加强公司对外接待及与外界的交流和 沟通，提高公司投资者关系管理水平，根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）《深圳证券 交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板 上市公司规范运作指引（2023 年修订）》等法律法规和规范性文件以及《公司章 程》的规定，结合公司实际情况，制订本制度。 第二条 本制度所述的机构调研接待工作，是指公司通过接受投资者、媒体、 证券机构的调研、一对一沟通、现场参观、分析师会议、路演和业绩说明会、新 闻采访等活动，增进资本市场对公司的了解和认同的工作。 第二章 目的和原则 第三条 制定本制度的目的在于规范公司在接受调研、采访、沟通或进行对 外宣传、推广等活动时，增加公司信息披露的透明度及公平性，改善公司治理结 构，增进资本市场对公司的了解和支持。 第四条 公司接待工作遵循以下 ...

申万宏源证券承销保荐有限责任公司 关于湖南汉森制药股份有限公司 2023 年度募集资金存放及使用情况的核查意见 申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承销保荐公司"、 "保荐机构"）作为湖南汉森制药股份有限公司（以下简称"汉森制药"、"公司"） 首次公开发行股票并上市的保荐机构，根据《证券发行上市保荐业务管理办法》、《深 圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》等法规和规范性文件的要求，对汉森制药 2023 年度募集资 金存放和使用进行了核查，具体情况如下： 一、保荐机构进行的核查工作 申万宏源承销保荐公司保荐代表人通过与公司财务负责人等谈话，询问募集资 金使用和项目建设情况，查询募集资金专户对账单、募集资金项目的明细账和款项 支付的原始凭证，了解募集资金项目工程建设情况，审阅年度募集资金存放与使用 的专项报告、会计师关于募集资金年度存放及实际使用情况的鉴证报告以及公司的 相关管理制度，从募集资金的管理、用途和信息披露情况等方面对其募集资金制度 的完整性、合理性及有效性进行了核查。 二、募集资金基本情况 （一）实际募集资金金额、资金到 ...

Financial Performance - The company's operating revenue for 2023 was ¥955,530,797.42, representing a 4.31% increase compared to ¥916,062,371.53 in 2022[17] - Net profit attributable to shareholders for 2023 was ¥205,014,883.78, a 22.31% increase from ¥167,615,535.76 in 2022[17] - The basic earnings per share for 2023 was ¥0.4074, up 22.31% from ¥0.3331 in 2022[17] - The total assets at the end of 2023 were ¥2,336,488,623.93, reflecting a 1.99% increase from ¥2,290,944,050.05 at the end of 2022[17] - The cash flow from operating activities for 2023 was ¥160,946,071.17, an 11.92% increase from ¥143,806,247.52 in 2022[17] - The weighted average return on equity for 2023 was 11.54%, an increase of 2.32% from 9.22% in 2022[17] - The net profit after deducting non-recurring gains and losses for 2023 was ¥205,216,869.31, a 22.97% increase from ¥166,889,693.07 in 2022[17] - The company reported a total net assets of ¥1,963,028,938.67 at the end of 2023, which is a 3.64% increase from ¥1,894,131,702.92 at the end of 2022[17] - The total profit reached 226.02 million yuan, reflecting a year-on-year growth of 24.29%[38] - The company achieved total operating revenue of 955.53 million yuan, a year-on-year increase of 4.31%[38] - Net profit attributable to shareholders reached CNY 205.01 million, an increase of 22.31% compared to the previous year[47] Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[4] - The company plans to continue investing in research and development to enhance product offerings and expand into new markets, focusing on generics and improving product quality[30] - The company aims to enhance its product structure and increase product reserves to ensure sustainable growth[30] - The company is actively expanding its market presence and product offerings, as indicated by discussions with institutional investors[95] - The company plans to enhance its research and development investments to adapt to intensified competition, emphasizing new product development and consistency evaluation of generic drugs[91] - The company will implement lean management across all operations to improve efficiency and reduce waste[91] - The company aims to achieve its 2024 operational goals by enhancing R&D efforts and ensuring compliance with safety and environmental standards[94] Market Position and Challenges - The company is positioned in the pharmaceutical manufacturing industry, benefiting from national policies aimed at promoting high-quality development in the sector[28] - The company is facing challenges such as rising raw material costs and intensified competition from both e-commerce and traditional channels[28] - The pharmaceutical industry is characterized by strong demand and limited seasonality, which supports the company's operational stability[29] - The company has a diverse product range, including traditional Chinese medicine and chemical drugs, catering to various health needs[31] Product Development and Innovation - The unique product "Si Mo Tang Oral Liquid" has established a strong market presence, being a key product in the company's portfolio and included in the national medical insurance directory[30] - In product research and development, the company has initiated studies on innovative traditional Chinese medicine and generic drugs, with several projects achieving milestone results[48] - The company completed the development of the generic version of Empagliflozin tablets and submitted the registration application to the National Medical Products Administration[65] - The company achieved a consistency evaluation for Iohexol injection, enhancing its product portfolio through consistency evaluation[65] Operational Efficiency and Management - The company has established a procurement management system to ensure stable supply channels for raw materials, utilizing both external procurement and self-owned planting bases[36] - The marketing strategy includes a three-pronged approach of decision-making, execution, and support, enhancing channel management and reducing price chaos[37] - The company maintains robust internal control management, ensuring stable production and sales while responding effectively to customer demands[46] - The company has implemented a digital management system to enhance operational efficiency and streamline workflows[49] - The company has established a value chain indicator system to improve performance management and operational efficiency[51] Financial Management and Governance - The company has independent financial departments and does not share bank accounts with its controlling shareholders[104] - The company maintains a governance structure that complies with relevant laws and regulations, ensuring independent operations from its controlling shareholder[100] - The board of directors and supervisory board operate independently, with independent directors actively participating in meetings and safeguarding minority shareholder interests[101] - The company has established a transparent performance evaluation system for its directors and senior management, ensuring accountability and clear reward mechanisms[102] - The company prioritizes information disclosure and investor relations, adhering to strict guidelines to enhance transparency and protect shareholder rights[103] Social Responsibility and Environmental Commitment - The company emphasizes employee rights protection, providing a safe working environment and comprehensive social insurance for all employees[139] - The company actively engages in social responsibility, contributing to local economic development and participating in community welfare activities[143] - The company has invested in environmental protection and clean production technologies to meet industry standards[142] - The company was recognized as a national green factory in March 2023 and achieved ISO 14001:2015 environmental management system certification in September 2023[136] Shareholder Relations and Equity Structure - The company reported a total of 26,339 shareholders at the end of the reporting period[180] - The total number of unrestricted shares increased to 497,845,000, representing 98.94% of the total shares outstanding after the adjustment[176] - The company has a total of 10 major shareholders, with the second largest being Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., holding 4.82% or 24,263,820 shares[182] - The report indicates that the actual controller of the company is a domestic natural person, with no changes in the controlling shareholder during the reporting period[183] Risk Management - The company acknowledges potential risks and uncertainties regarding its future operational capabilities[3] - The company faces risks related to policy changes in the pharmaceutical industry, reliance on its leading product, and potential raw material procurement issues[92] - The company has not reported any significant uncertainties regarding its ability to continue as a going concern, suggesting a stable operational outlook[200]